NEW YORK, Aug. 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Ocular Therapeutix, Inc. ("Ocular Therapeutix") (NASDAQ:OCUL) between March 10, 2016 and July 11, 2017. You are hereby notified that Levi & Korsinsky filed Kim v. Ocular Therapeutix, Inc., a securities class action lawsuit in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-sba/ocular-therapeutix-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Ocular Therapeutix you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Washington Post Publisher Will Lewis Steps Down After Layoffs
Instagram Outage Disrupts Thousands of U.S. Users
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



